Investor Presentation Q1 2023
6
Investor presentation
First three months of 2023
Diabetes value market leadership increased by 1.7%-points to
32.2%
Novo Nordisk global diabetes value market shares
Diabetes value market leadership expansion
driven by the GLP-1 franchise
60%
-Diabetes
-GLP-1
-Insulin
54.4%
53.6%
50.8%
48.3%
50%
Novo NordiskⓇ
Diabetes care sales grew by 21% (CER) with global value market
share increase driven by GLP-1 market share gains in both IO and
NAO. Global diabetes care market volume growth was ~4%
GLP-1 value market share has increased by 0.8%-points in the last
12 months, driven by:
44.5%
44.1%
44.0%
44.5%
40%
.
32.2%
30.5%
28.8%
29.3%
30%
0% T
2020
2021
2022
2023
CER: Constant exchange rates; IO: International Operations; NAO: North America Operations
Note: Sales growth rates are at CER
Source: IQVIA MAT, Feb 2023 (Spot rate); Volume growth based on Moving Annual Total (MAT)
•
Global GLP-1 volume growth of ~50%
Estimated global GLP-1 share of total diabetes
prescriptions is ~5%View entire presentation